GNTA
Genenta Science S.p.A.
NASDAQ · Healthcare · Biotechnology · IT
$0.99
+4.16%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | — | — |
| Cost of Revenue | 72.7K | 27.0K | 46.5K | 41.7K | 6.0K |
| Gross Profit | (72.7K) | (27.0K) | (46.5K) | (41.7K) | (6.0K) |
| Operating Expenses | |||||
| R&D Expense | 7.5M | 2.6M | 5.0M | 6.4M | 5.2M |
| SG&A Expense | 8.8M | 3.7M | 5.1M | 5.1M | 5.6M |
| General & Admin Expense | — | — | — | — | — |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 16.3M | 6.3M | 10.2M | 11.5M | 10.8M |
| Cost and Expenses | 16.4M | 6.3M | 10.2M | 11.5M | 10.8M |
| Operating Income (EBIT) | (16.4M) | (6.3M) | (10.2M) | (11.5M) | (10.8M) |
| Non-Operating | |||||
| Interest Income | 968.4K | 968.7K | — | — | — |
| Interest Expense | 373.5K | 384.2K | — | — | — |
| Net Interest Income | 594.9K | 584.5K | — | — | — |
| Other Non-Op Income/Expense | 972.2K | 71.0K | 889.8K | 85.9K | 2.5M |
| Non-Operating Income (excl Interest) | (1.3M) | (455.2K) | (889.8K) | (85.9K) | (2.5M) |
| EBT (Pre-Tax Income) | (15.4M) | (6.3M) | (9.3M) | (11.4M) | (8.3M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (15.4M) | (6.3M) | (9.3M) | (11.4M) | (8.3M) |
| Earnings from Cont. Ops | (15.4M) | (6.3M) | (9.3M) | (11.4M) | (8.3M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (15.4M) | (6.3M) | (9.3M) | (11.4M) | (8.3M) |
| Per Share | |||||
| Basic EPS | ($0.82) | ($0.33) | ($0.49) | ($0.64) | ($0.47) |
| Diluted EPS | ($0.82) | ($0.33) | ($0.49) | ($0.64) | ($0.47) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 21.2M | 19.7M | 18.3M | 18.2M | 18.2M |
| Diluted Shares Outstanding | 21.2M | 19.7M | 18.3M | 18.2M | 18.2M |
| Profitability Metrics | |||||
| EBITDA | (15.0M) | (5.9M) | (9.3M) | (11.4M) | (8.3M) |
| D&A | 72.7K | 27.0K | 46.5K | 41.7K | 6.0K |
| EBIT | (15.0M) | (5.9M) | (9.3M) | (11.4M) | (8.3M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Dec 1, 2025